BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

Caparica, Rafael; Castro, Gilberto de; Gil-Bazo, Ignacio; Caglevic, Christian; Calogero, Raffaele; Giallombardo, Marco; Santos, Edgardo S.; Raez, Luis E.; Rolfo, Christian

doi:10.1016/j.critrevonc.2016.02.012

Cited by 15 publications

(10 citation statements)

References 57 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several new targeted therapies have been recently approved for non-squamous NSCLC that inhibit Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor Receptor (EGFR), Anaplastic Lymphoma Kinase (ALK), and Reactive Oxygen Species (ROS-1) [61]. As more driver mutations are discovered and therapeutic compounds developed to target these abnormal pathways, precise diagnosis of lung cancer and its subtypes will be crucial [62]. Protein expression and signalling in either BALF or plasma may have clinical relevance in the future through its ability to precisely differentiate subtypes and facilitate lung cancer diagnosis.…”

Section: Discussionmentioning

confidence: 99%

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry

et al. 2017

View full text Add to dashboard Cite

BackgroundLung cancer is the leading cause of cancer-related mortality in both men and women throughout the world. The need to detect lung cancer at an early, potentially curable stage, is essential and may reduce mortality by 20%. The aim of this study was to identify distinct proteomic profiles in bronchoalveolar fluid (BALF) and plasma that are able to discriminate individuals with benign disease from those with non-small cell lung cancer (NSCLC).MethodsUsing label-free mass spectrometry analysis of BALF during discovery-phase analysis, a significant number of proteins were found to have different abundance levels when comparing control to adenocarcinoma (AD) or squamous cell lung carcinoma (SqCC). Validation of candidate biomarkers identified in BALF was performed in a larger cohort of plasma samples by detection with enzyme-linked immunoassay.ResultsFour proteins (Cystatin-C, TIMP-1, Lipocalin-2 and HSP70/HSPA1A) were selected as a representative group from discovery phase mass spectrometry BALF analysis. Plasma levels of TIMP-1, Lipocalin-2 and Cystatin-C were found to be significantly elevated in AD and SqCC compared to control.ConclusionThe results presented in this study indicate that BALF is an important proximal biofluid for the discovery and identification of candidate lung cancer biomarkers.General significanceThere is good correlation between the trend of protein abundance levels in BALF and that of plasma which validates this approach to develop a blood biomarker to aid lung cancer diagnosis, particularly in the era of lung cancer screening. The protein signatures identified also provide insight into the molecular mechanisms associated with lung malignancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry

et al. 2017

View full text Add to dashboard Cite

show abstract

“…BRAF (a proto-oncogene) encoding a Ser-Thr kinase protein which is a downstream effector protein in the RAS/RAF/ERK signaling pathway can directly phosphorylate the MEK and even activate the ERK to affect the cells proliferation and survival [ 65 – 69 ]. BRAF is one of members of the RAF kinase family including ARAF, BRAF, and RAF1 (also named cRAF) [ 70 ].…”

Section: Introductionmentioning

confidence: 99%

Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies

et al. 2017

View full text Add to dashboard Cite

Lung cancer is one of the most common causes of cancer-related death in the world. The large number of lung cancer cases is non-small cell lung cancer (NSCLC), which approximately accounting for 75% of lung cancer. Over the past years, our comprehensive knowledge about the molecular biology of NSCLC has been rapidly enriching, which has promoted the discovery of driver genes in NSCLC and directed FDA-approved targeted therapies. Of course, the targeted therapies based on driver genes provide a more exact option for advanced non-small cell lung cancer, improving the survival rate of patients. Now, we will review the landscape of driver genes in NSCLC including the characteristics, detection methods, the application of target therapy and challenges.

show abstract

“…The regulative domain is found among exons 1-10 within the amino (N) terminus, whereas the enzyme domain is found among exons 11-18 at the carboxyl (C) terminus ( Fig. 3) [17,[42][43][44][45][46].…”

Section: Brafmentioning

confidence: 99%

A Review: Status of Genetic Modulated Nonsmall Cell Lung Cancer Targets and Treatment (Current Updates in Drugs for Non-Small Cell Lung Cancer Treatment)

Kumar

Purohit

Dagar

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Genetic modifications or mutations has been a bottleneck for the treatment of cancer; it is widely known to play a vital role in the progression of metastatic level/stage within the nonsmall cell lung cancer (NSCLC). The NSCLC of cancer is responsible for lung cancer lawsuits. In the various genetic mutations related study has been concluded with the various genes findings, which are named as the epidermal growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma virus, ROS proto-oncogene 1, human epidermal growth factor, B-RAF proto-oncogene, rearranged during Transfection, MET, Phosphatidyl 3-kinases CA, IGF-1R, NTRK1, FGFR1, and DDR2. The various research data supported this study. The involvement of the gene in the NSCLC patients made a paradigm shift in the drug discovery. The presence of one mutation in connection with some other could have an impact on NSCLC remedy.Utilizing this genotype-directed therapy for an advanced NSCLC has to turn out to be an appealing and efficacious treatment strategy. Here in the advancement of research, related genetic modulated targets and treatment have been discussed, particular genetic mutations help to find new updated interventions or medicinal drugs for the treatment of NSCLC. In there view, we have comprehensively arranged the mutation type and treatment with the status of NSCLC.

show abstract

BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?

Cited by 15 publications

References 57 publications

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry

Proteomic analysis of bronchoalveolar lavage fluid (BALF) from lung cancer patients using label-free mass spectrometry

Driver genes in non-small cell lung cancer: Characteristics, detection methods, and targeted therapies

A Review: Status of Genetic Modulated Nonsmall Cell Lung Cancer Targets and Treatment (Current Updates in Drugs for Non-Small Cell Lung Cancer Treatment)

Contact Info

Product

Resources

About